Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monthly ibandronate for prevention of glucocorticoid-induced osteoporosis in postmenopausal women
2006-000011-15Phase 4Completed
- Sponsor
- Roche
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in glucocorticoid-induced osteoporosis (GIOP) and osteoporosis comparing Ibandronate 150 mg once monthly with Placebo once monthly (2 arms). Primary endpoint: Change in lumbar spine bone mineral density at 12 months. Started Feb 2006; status: completed.
02
Drugs
ibandronate
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)osteoporosis
Beyond the preview
Go deeper on 2006-000011-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000011-15.